William King

Authored Items
Belantamab Induces Clinically Meaningful Responses in Heavily Pretreated Patients with Multiple Myeloma
William King
TOP - March 2021 Vol 14, No 2 in ASH 2020 Highlights
Umbralisib plus Ublituximab Regimen Superior to Chemoimmunotherapy in CLL
William King
TOP - March 2021 Vol 14, No 2 in ASH 2020 Highlights
Pevonedistat plus Azacitidine Combination Shows Encouraging Activity in Higher-Risk MDS
William King
TOP - March 2021 Vol 14, No 2 in ASH 2020 Highlights
First-Line Combinations Show Promise in the Treatment of Advanced Renal-Cell Carcinoma
William King
TOP - January 2021 Vol 14, No 1 in Renal-Cell Carcinoma
Novel Drug Combinations Achieving Undetectable Minimal Residual Disease in Patients with CLL
William King
TOP - January 2021 Vol 14, No 1 in Hematologic Malignancies
Targeting HIF-2 Has the Potential to Improve Outcomes for Patients with Clear-Cell Renal-Cell Carcinoma
William King
TOP - January 2021 Vol 14, No 1 in Renal-Cell Carcinoma
Strategies for Lowering the Cost of Cancer Care
William King
TOP - November 2020 Vol 13, No 6 in NCCN
The Impact of COVID-19 on the Oncology Care Model
William King
TOP - November 2020 Vol 13, No 6 in NCCN
AACR’s Cancer Disparities Progress Report Highlights Need for Healthcare Equity
William King
TOP - November 2020 Vol 13, No 6 in Disparities in Oncology
Tumor-Infiltrating Lymphocytes Show Promising Activity in Patients with Advanced Melanoma
William King
TOP - November 2020 Vol 13, No 6 in Emerging Therapies
Experts Agree That Innovation Is Key to Improving Value-Based Care
William King
TOP - November 2020 Vol 13, No 6 in NCCN
Few Actionable Genomic Alterations Identified in Renal-Cell Carcinoma
William King
TOP - September 2020 Vol 13, No 5 in Renal-Cell Carcinoma
Capmatinib Shows Promise in MET-Amplified Non–Small-Cell Lung Cancer
William King
TOP - September 2020 Vol 13, No 5 in Lung Cancer
Adjuvant Treatment with Osimertinib Is Highly Effective in EGFR-Mutated Earlier-Stage NSCLC
William King
TOP - September 2020 Vol 13, No 5 in Lung Cancer
Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular Lymphoma and Marginal-Zone Lymphoma
William King
TOP - September 2020 Vol 13, No 5 in Lymphoma
Nivolumab plus Ipilimumab May Be a New First-Line Option for Patients with MSI-H or dMMR Metastatic Colorectal Cancer
William King
TOP - September 2020 Vol 13, No 5 in Colorectal Cancer
Adavosertib Monotherapy Demonstrates Promising Clinical Activity in Uterine Serous Cancer
William King
TOP - September 2020 Vol 13, No 5 in Emerging Therapies, Gynecologic Cancers
Pembrolizumab Added to First-Line Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
William King
TOP - September 2020 Vol 13, No 5 in Breast Cancer
Last modified: August 17, 2020